KRMD Stock Analysis: KORU Medical Systems | NASDAQ

Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 145m USD | 12M Return: 4.3% | US7599101026 | Charts, Fundamentals & Technical Analysis

Total Rating 48
Safety 58
Buy Signal -0.14
Medical Instruments & Supplies
Industry Rotation: +8.9
Market Cap: 145M
Avg Turnover: 446K
Risk 3d forecast
Volatility142%
VaR 5th Pctl21.7%
VaR vs Median-6.69%
Reward TTM
Sharpe Ratio0.27
Rel. Str. IBD46.9
Rel. Str. Peer Group35.2 pctl
Character TTM
Beta1.177
Beta Downside0.487
Hurst Exponent0.455
Choppyness53.6%
Drawdowns 3y
Max DD57.96%
CAGR/Max DD0.37
CAGR/Mean DD0.95
EPS (Earnings per Share) EPS (Earnings per Share) of KRMD over the last years for every Quarter: "2021-09": -0.02, "2021-12": -0.02, "2022-03": -0.05, "2022-06": -0.06, "2022-09": -0.03, "2022-12": -0.04, "2023-03": -0.05, "2023-06": -0.05, "2023-09": -0.03, "2023-12": -0.03, "2024-03": -0.02, "2024-06": -0.01, "2024-09": -0.01, "2024-12": -0.03, "2025-03": -0.03, "2025-06": 0.01, "2025-09": -0.0168, "2025-12": 0.01, "2026-03": -0.0174, "2026-06": 0.01, "2026-09": 0.02,
Last SUE: 2.37
Qual. Beats: 2
Revenue Revenue of KRMD over the last years for every Quarter: 2021-09: 6.040544, 2021-12: 6.490506, 2022-03: 6.24433, 2022-06: 6.546628, 2022-09: 7.760398, 2022-12: 7.344681, 2023-03: 7.392605, 2023-06: 6.935931, 2023-09: 7.003198, 2023-12: 7.185932, 2024-03: 8.197798, 2024-06: 8.430089, 2024-09: 8.179977, 2024-12: 8.838599, 2025-03: 9.635075, 2025-06: 10.1948, 2025-09: 10.402163, 2025-12: 10.895328, 2026-03: 11.764624, 2026-06: 12.04542, 2026-09: null,
Rev. CAGR: 19.53%
Rev. Trend: 99.2%
Last SUE: 1.22
Qual. Beats: 2

Warnings

Altman Z'' In Financial Distress Zone
Overextended 3d
Below Sma 200d

Tailwinds

Ep Pivot

Seasonality

Not enough history
Description: KRMD KORU Medical Systems
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Headlines to Watch Out For
Piotroski VR-10 (Strict) 3.5
Net Income: -1.82m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 9.54 > 1.0
NWC/Revenue: 27.34% < 20% (prev 31.29%; Δ -3.94% < -1%)
CFO/TA 0.05 > 3% & CFO 1.39m > Net Income -1.82m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.72 > 1.5 & < 3
Outstanding Shares: last quarter (49.5m) vs 12m ago 7.18% < -2%
Gross Margin: 61.99% > 18% (prev 63.15%; Δ -1.16% > 0.5%)
Asset Turnover: 168.7% > 50% (prev 144.4%; Δ 24.28% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 0.55
A: 0.44 (Total Current Assets 19.5m - Total Current Liabilities 7.18m) / Total Assets 28.0m
B: -1.16 (Retained Earnings -32.6m / Total Assets 28.0m)
C: -0.07 (EBIT TTM -1.81m / Avg Total Assets 26.7m)
D: 1.82 (Book Value of Equity 18.1m / Total Liabilities 9.91m)
Altman-Z'' = 0.55 = B
Beneish M -2.28
DSRI: 0.98 (Receivables 6.09m/5.09m, Revenue 45.1m/36.8m)
GMI: 1.02 (GM 63.15% / 61.99%)
AQI: 2.02 (AQ_t 0.06 / AQ_t-1 0.03)
SGI: 1.22 (Revenue 45.1m / 36.8m)
TATA: -0.11 (NI -1.82m - CFO 1.39m) / TA 28.0m)
Beneish M = -2.28 (Cap -4..+1) = BBB
What is the price of KRMD shares?

As of November 12, 2026, the stock is trading at USD 3.89 with a total of 722,940 shares traded. Over the past week, the price has changed by +18.96%, over one month by +30.98%, over three months by +12.75% and over the past year by +4.29%.

Current recommended Stop Loss: 3.60 (which is 7.5% or 1.7 ATR below the current price).

Is KRMD a buy, sell or hold?

KORU Medical Systems has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KRMD.

  • StrongBuy: 3
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the KRMD price?
Analysts Target Price 6.3 60.7%
KORU Medical Systems (KRMD) - Fundamental Data Overview as of 12 November 2026
Market Cap USD = 145.1m (145.1m USD * 1.0 USD.USD)
P/E Forward = 80.6452
P/S = 3.2178
P/B = 8.2361
Revenue TTM = 45.1m USD
EBIT TTM = -1.81m USD
EBITDA TTM = -1.02m USD
Long Term Debt = 2.66m USD (estimated: total debt 3.24m - short term 579k)
Short Term Debt = 579k USD (from shortTermDebt, last quarter)
Debt = 3.24m USD (from shortLongTermDebtTotal, last quarter) (leases 3.31m already included)
Net Debt = -5.05m USD (calculated: Debt 3.24m - CCE 8.29m)
Enterprise Value = 140.1m USD (145.1m + Debt 3.24m - CCE 8.29m)
 Interest Coverage Ratio = unknown (Ebit TTM -1.81m / Interest Expense TTM 0.0)
 EV/FCF = 531.7x (Enterprise Value 140.1m / FCF TTM 263k)
FCF Yield = 0.19% (FCF TTM 263k / Enterprise Value 140.1m)
FCF Margin = 0.58% (FCF TTM 263k / Revenue TTM 45.1m)
Net Margin = -4.03% (Net Income TTM -1.82m / Revenue TTM 45.1m)
Gross Margin = 61.99% ((Revenue TTM 45.1m - Cost of Revenue TTM 17.1m) / Revenue TTM)
Gross Margin QoQ = 65.14% (prev 59.79%)
Tobins Q-Ratio = 5.01 (Enterprise Value 140.1m / Total Assets 28.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.24m)
Taxrate = 2.25% (5.80k / 258k)
NOPAT = -1.77m (EBIT -1.81m * (1 - 2.25%)) [loss with tax shield]
Current Ratio = 2.72 (Total Current Assets 19.5m / Total Current Liabilities 7.18m)
Debt / Equity = 0.18 (Debt 3.24m / totalStockholderEquity, last quarter 18.1m)
 Debt / EBITDA = 4.96 (negative EBITDA) (Net Debt -5.05m / EBITDA -1.02m)
 Debt / FCF = -19.17 (Net Debt -5.05m / FCF TTM 263k)
Total Stockholder Equity = 17.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.80% (Net Income -1.82m / Total Assets 28.0m)
RoE = -10.63% (Net Income TTM -1.82m / Total Stockholder Equity 17.1m)
RoCE = -9.15% (EBIT -1.81m / Capital Employed (Equity 17.1m + L.T.Debt 2.66m))
 RoIC = -9.26% (negative operating profit) (NOPAT -1.77m / Invested Capital 19.1m)
 WACC = 9.38% (E(145.1m)/V(148.4m) * Re(9.59%) + D(3.24m)/V(148.4m) * Rd(0.0%) * (1-Tc(0.02)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 66.99 | Cagr: 3.61%
[DCF] Terminal Value 71.90% ; FCFF base≈263k ; Y1≈265k ; Y5≈280k
[DCF] Fair Price = 0.19 (EV 3.71m - Net Debt -5.05m = Equity 8.76m / Shares 45.9m; r=9.38% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.37 | # QB: 2
Revenue Correlation: 99.25 | Revenue CAGR: 19.53% | SUE: 1.22 | # QB: 2
EPS current Year (2026-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | GrowthEPS=-150.0% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=0.04 | Chg30d=-56.25% | Revisions=+0% | GrowthEPS=+800.0% | GrowthRev=+17.2%
[Analyst] Revisions Ratio: +0% (up=1, down=1)